February 27, 2025 — Vilnius, Lithuania — Oxipit, a leading AI-driven healthcare technology company, has announced the appointment of Dr. Robert Epstein to its Radiology Advisory Board. His expertise in radiology and healthcare strategy will support Oxipit’s mission to enhance diagnostic workflows worldwide through trusted AI solutions, enabling faster, more precise diagnoses and advancing patient care.
Dr. Epstein, a recognized leader in the field, brings over three decades of clinical and industry experience. His appointment strengthens Oxipit’s commitment to addressing key challenges in radiology, including increasing imaging volumes and the growing strain on healthcare systems.
“Oxipit stands out with a groundbreaking approach to solving some of the biggest challenges in radiology,” said Dr. Epstein. “Their ability to detect 75 pathologies confidently identify normal chest X-rays, and triage negative cases is unmatched—not only in the U.S. market, but globally as well. As radiologists face seemingly endless worklists, Oxipit’s technology provides a robust, practical solution to streamline workflows while maintaining accuracy, enhancing patient care and decreasing radiologist burnout. I am honored to join their mission to redefine diagnostic workflows and support radiologists in delivering exceptional care.”
Founded in 2017 and headquartered in Vilnius, Lithuania, Oxipit is at the forefront of AI innovation in radiology. Its comprehensive Chest Suite combines autonomous reporting, workflow optimization, and real-time quality assurance to support radiologists in delivering faster, more precise diagnoses. With a growing global footprint, Oxipit is preparing for an expanded presence in the U.S., where FDA clearance for its solutions is currently pending.
“Dr. Epstein’s expertise and insights come at a critical time as we focus on introducing our solutions to the U.S. healthcare market,” said Peter Corscadden, CEO of Oxipit. “His guidance will be instrumental in helping us demonstrate the value and impact of autonomous reporting in radiology.”
Oxipit’s solutions are designed to integrate seamlessly into existing clinical workflows, reducing routine tasks and allowing radiologists to focus on complex cases. This approach supports more efficient operations and improved diagnostic confidence.
About Oxipit
Founded in 2017 by experts in medicine and data science, Oxipit is a leader in AI-driven medical imaging. In 2019, the company received CE certification for ChestEye, enabling preliminary reports for 75 chest X-ray findings. Building on this success, Oxipit launched ChestLink in April 2022—the world’s first CE Class IIb-certified autonomous AI imaging application—capable of identifying normal chest X-ray studies with 99.9% sensitivity. Oxipit empowers radiologists by automating routine cases, allowing them to focus on complex and high-priority cases, while enhancing diagnostic accuracy and improving patient outcomes. Trusted by healthcare providers worldwide, Oxipit continues to advance AI-powered diagnostics, shaping the future of medical imaging.